Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Odanacatib on Bone Mineral Density in Postmenopausal Women
2008-004504-31Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in osteoporosis and low bone mineral density comparing Odanacatib + vitamin D with Placebo + vitamin D (2 arms). Primary endpoint: Areal BMD at the lumbar spine (12 months). Started Jul 2008; status: terminated.
02
Drugs
odanacatib
03
Conditions
osteoporosislow bone mineral density
Beyond the preview
Go deeper on 2008-004504-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004504-31.